Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12091411 IRAK degraders and uses thereof

Patent 12091411 was granted and assigned to Kymera Therapeutics on September, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Kymera Therapeutics

0

Current Assignee

Kymera Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Chris De Savi0

Bruce C. Follows0

Xiao Zhu0

Matthew M. Weiss0

Nello Mainolfi0

Xiaozhang Zheng0

Date of Patent

September 17, 2024

0

Patent Application Number

181623650

Date Filed

January 31, 2023

0

Patent Citations

US Patent 7208157 Proteolysis targeting chimeric pharmaceutical

0

US Patent 7273920 Controlling protein levels in eucaryotic organisms

0

US Patent 7307077 Heterocyclic compound and antitumor agent containing the same as effective ingredient

0

US Patent 7390799 Apoptosis promoters

0

US Patent 7402325 Supercritical carbon dioxide extract of pharmacologically active components from

0

US Patent 6949537 PI-3 kinase inhibitor prodrugs

0

US Patent 7041298 Proteolysis targeting chimeric pharmaceutical

0

US Patent 7071189 Heterocyclic compound and antitumor agent containing the same as active ingredient

0

...

Patent Primary Examiner

Matthew P Coughlin

0

CPC Code

0

Patent abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12091411 IRAK degraders and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool